Compare CSX Corporation (CSX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs TG Therapeutics Inc — how do they compare? CSX Corporation trades at $47.31 (market cap $87.70B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: CSX Corporation is far larger — about 10.7× TG Therapeutics Inc's market cap, and CSX Corporation pays a 1.18% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and TG Therapeutics Inc for 16 Days on average.
| CSX | TGTX | |
|---|---|---|
Market Cap | $87.70B | $8.16B |
Volume | 6,980,781 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $53.21 | $59.06 |
52-Week Low | $33.68 | $26.94 |
Typical Hold Time | 55 Days | 16 Days |
Enterprise Value | $105.66B | $8.37B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.28, up 0.99% today, with a bullish technical signal and strong institutional interest. The railroad operator shows solid profitability with 22.2% net margins and 24.4% ROE, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analysts maintain a buy consensus with a $51 target, representing 8% upside. Recent news highlights upcoming Q3 earnings and institutional acquisitions.
CSX offers moderate upside potential with strong operational metrics offset by revenue pressures. Key opportunities include pricing power in freight rail and dividend growth, while risks involve economic sensitivity and competitive threats. The stock's premium valuation requires sustained execution to justify current levels.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
